The role of brigatinib in crizotinib-resistant non-small cell lung cancer
Laura Mezquita, David Planchard Medical Oncology Department, Gustave Roussy, Villejuif, France Abstract: Despite the advances in new targeted therapies in ALK positive population, most patients progress under ALK inhibitors within first 2 years; being the brain the most frequent site of rel...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-01-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-role-of-brigatinib-in-crizotinib-resistant-non-small-cell-lung-can-peer-reviewed-article-CMAR |